Moderna, with its mission to deliver the greatest possible impact to people through mRNA medicines, welcomes the overall objectives of the revision of the General Pharma Legislation (GPL) as proposed by the Commission to create an innovative and competitive EU healthcare ecosystem, to invest in R&D, and to provide early innovative medicines to patients.
MOD
Moderna
Company · Netherlands · EU Transparency Register 011080341579-06
2
positions filed
in the 583 files tracked
1
legislative file
of 583 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1048 companies & groups on this site, they rank #672 by legislative files engaged — a count of participation, not a measure of influence.
0.6
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2021
in the register since
Declares membership of
- VE - Vaccines Europe (https://www.vaccineseurope.eu)
- Eucope - European Confederation of Pharmaceutical Entrepreneurs AISBL (www.eucope.org)
- IFPMA - International Federation of PHarmaceutical Manufacturers & Associations (www.ifpma.org)
- BIO - Biotechnology Innovation Organization (www.bio.org)
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Companies & groups
- Registered as
- Moderna, Inc.
- Head office
- Cambridge, United states
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Moderna in PolicySpeak: request access →
Work at Moderna? so we know who speaks for it.
Their record over time
Moderna filed 2 positions on 8 Nov 2023, across 1 of the 583 legislative files tracked here, attaching a full position paper 2 times.
What they argued
Moderna, with its mission to deliver the greatest possible impact to people through mRNA medicines, welcomes the overall objectives of the revision of the General Pharma Legislation (GPL) as proposed by the Commission to create an innovative and competitive EU healthcare ecosystem, to invest in R&D, and to provide early innovative medicines to patients.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Moderna next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from Moderna’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.